SV2010003704A - MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME - Google Patents
MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAMEInfo
- Publication number
- SV2010003704A SV2010003704A SV2010003704A SV2010003704A SV2010003704A SV 2010003704 A SV2010003704 A SV 2010003704A SV 2010003704 A SV2010003704 A SV 2010003704A SV 2010003704 A SV2010003704 A SV 2010003704A SV 2010003704 A SV2010003704 A SV 2010003704A
- Authority
- SV
- El Salvador
- Prior art keywords
- factor
- modified
- polipeptides
- same
- polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE DIVULGAN POLIPÉPTIDOS MODIFICADOS DEL FACTOR IX, TALES COMO LOS POLIPÉPTIDOS DEL FACTOR IX CON UNO O MÁS SITIOS DE GLICOSILACIÓN INTRODUCIDOS. LOS POLIPÉPTIDOS MODIFICADOS DEL FACTOR IX PUEDEN EXHIBIR UN INCREMENTO DE LA ESTABILIDAD IN VITRO O IN VIVO, TAL COMO UNA SEMIVIDA PLASMÁTICA MAS PROLONGADA. ASIMISMO SE DIVULGAN PROCEDIMIENTOS DE FABRICAR POLIPÉPTIDOS MODIFICADOS DEL FACTOR IX Y A PROCEDIMIENTOS DE USAR MODIFICADOS DEL FACTOR IX PARA, POR EJEMPLO, TRATAR A PACIENTES AFECTADOS POR HEMOFILIA BMODIFIED FACTOR IX POLYPEPTIDES ARE DISCLOSED, SUCH AS THE FACTOR IX POLYPEPTIDES WITH ONE OR MORE INTRODUCED GLYCOSILATION SITES. MODIFIED POLIPEPTIDES OF FACTOR IX MAY EXHIBIT AN INCREASE OF STABILITY IN VITRO OR IN VIVO, SUCH AS A MOST PROLONGED PLASMATIC SEMIVIDE. Likewise, PROCEDURES FOR MANUFACTURING MODIFIED POLIPEPTIDES OF FACTOR IX ARE DISCLOSED AND PROCEDURES FOR USING MODIFIED FACTOR IX FOR, FOR EXAMPLE, TREATING PATIENTS AFFECTED BY HEMOPHILIA B
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12456708P | 2008-04-16 | 2008-04-16 | |
US4596108P | 2008-04-17 | 2008-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2010003704A true SV2010003704A (en) | 2011-02-21 |
Family
ID=41265284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2010003704A SV2010003704A (en) | 2008-04-16 | 2010-10-15 | MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP2288622A4 (en) |
JP (1) | JP2011517951A (en) |
KR (1) | KR20110005862A (en) |
CN (1) | CN102083856A (en) |
AU (1) | AU2009244633A1 (en) |
BR (1) | BRPI0910702A2 (en) |
CA (1) | CA2721683A1 (en) |
CO (1) | CO6311000A2 (en) |
CR (1) | CR11737A (en) |
DO (1) | DOP2010000311A (en) |
EC (1) | ECSP10010551A (en) |
IL (1) | IL208718A0 (en) |
MX (1) | MX2010011345A (en) |
RU (1) | RU2010146387A (en) |
SG (1) | SG189790A1 (en) |
SV (1) | SV2010003704A (en) |
WO (1) | WO2009137254A2 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2084274A2 (en) * | 2006-06-19 | 2009-08-05 | Nautilus Technology LLC | Modified coagulation factor ix polypeptides and use thereof for treatment |
JP5613876B2 (en) * | 2007-10-15 | 2014-10-29 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Human factor IX variants with extended half-life |
DK3581650T3 (en) | 2008-09-15 | 2023-03-13 | Uniqure Biopharma B V | FACTOR IX POLYPEPTIDE MUTANT, USE THEREOF AND A PROCEDURE FOR MANUFACTURE THEREOF |
UA115120C2 (en) | 2010-07-09 | 2017-09-25 | Байоджен Хемофіліа Інк. | Factor ix polypeptides and methods fo use thereof |
AU2013204511B2 (en) * | 2010-11-03 | 2016-03-17 | Gc Biopharma Corp. | Modified factor ix polypeptides and uses thereof |
TWI557135B (en) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | Modified factor ix polypeptides and uses thereof |
EP3527218A1 (en) | 2011-06-10 | 2019-08-21 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
US10656167B2 (en) | 2011-07-25 | 2020-05-19 | Bioverativ Therapeutics Inc. | Assays to monitor bleeding disorders |
JP5967631B2 (en) * | 2012-04-27 | 2016-08-10 | 学校法人日本大学 | Treatment for epithelial and endothelial damage |
US10001495B2 (en) | 2012-07-25 | 2018-06-19 | Bioverativ Therapeutics Inc. | Blood factor monitoring assay and uses thereof |
WO2014052490A1 (en) | 2012-09-25 | 2014-04-03 | Biogen Idec Ma Inc. | Methods of using fix polypeptides |
EP2908847B1 (en) | 2012-10-18 | 2022-03-30 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
DK3889173T3 (en) | 2013-02-15 | 2023-10-09 | Bioverativ Therapeutics Inc | OPTIMIZED FACTOR VIII GENE |
UY35463A (en) | 2013-03-15 | 2014-10-31 | Biogen Idec Inc | FC-FACTOR IX POLYPEPTIDE FORMULATIONS IX. |
HUE057005T2 (en) | 2013-09-25 | 2022-04-28 | Bioverativ Therapeutics Inc | On-column viral inactivation methods |
WO2015070014A1 (en) | 2013-11-08 | 2015-05-14 | Biogen Idec Ma Inc. | Procoagulant fusion compound |
US10325687B2 (en) | 2013-12-06 | 2019-06-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
JP2017500017A (en) | 2013-12-20 | 2017-01-05 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
KR102385372B1 (en) | 2014-03-24 | 2022-04-11 | 바이오버라티브 테라퓨틱스 인크. | Lyophilized factor ix formulations |
WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
AU2016301303B2 (en) | 2015-08-03 | 2021-10-07 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
PT3411478T (en) | 2016-02-01 | 2022-09-13 | Bioverativ Therapeutics Inc | Optimized factor viii genes |
CN105695616A (en) * | 2016-04-22 | 2016-06-22 | 王冬国 | Analysis marker for diagnosing thyroid cancer and application thereof |
EP3548066A1 (en) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
TW201831521A (en) | 2017-01-31 | 2018-09-01 | 美商生物化學醫療公司 | Factor IX fusion proteins and methods of making and using same |
FR3069540B1 (en) | 2017-07-28 | 2019-09-13 | Universite Claude Bernard Lyon 1 | MODIFIED PROTEIN WITH IMPROVED HALF-LIFE |
SG11202000764RA (en) | 2017-08-09 | 2020-02-27 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
MX2020003351A (en) | 2017-09-27 | 2020-10-12 | Sigilon Therapeutics Inc | Methods, compositions, and implantable elements comprising active cells. |
US11491212B1 (en) | 2017-09-27 | 2022-11-08 | Catalyst Biosciences, Inc. | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B |
TW202014181A (en) | 2018-04-04 | 2020-04-16 | 美商希吉隆醫療公司 | Implantable particles and related methods |
US20210145889A1 (en) | 2018-04-04 | 2021-05-20 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
AU2019270184A1 (en) | 2018-05-18 | 2020-11-26 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
MX2021001599A (en) | 2018-08-09 | 2021-07-02 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof for non-viral gene therapy. |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
UY38389A (en) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
KR20220009389A (en) | 2019-04-17 | 2022-01-24 | 코디악 바이오사이언시즈, 인크. | Composition of exosomes and AAV |
WO2021154414A2 (en) | 2020-01-29 | 2021-08-05 | Catalyst Biosciences, Inc. | Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides |
CA3209399A1 (en) | 2021-02-24 | 2022-09-01 | Michael Thomas Pace | System and method for a digitally beamformed phased array feed |
WO2024081310A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
WO2024081309A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2638643B1 (en) * | 1988-11-09 | 1991-04-12 | Transgene Sa | DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM |
US6531298B2 (en) * | 1997-07-21 | 2003-03-11 | The University Of North Carolina At Chapel Hill | Factor IX antihemophilic factor with increased clotting activity |
WO2003020764A2 (en) * | 2001-09-04 | 2003-03-13 | Merck Patent Gmbh | Modified factor ix |
MXPA05010846A (en) * | 2003-04-09 | 2006-03-30 | Nektar Therapeutics | Hemophilia treatment by inhalation of coagulation factors. |
US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
AU2004296860B2 (en) * | 2003-12-03 | 2010-04-22 | Novo Nordisk A/S | Glycopegylated factor IX |
EP2084274A2 (en) * | 2006-06-19 | 2009-08-05 | Nautilus Technology LLC | Modified coagulation factor ix polypeptides and use thereof for treatment |
US7700734B2 (en) * | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
-
2009
- 2009-04-16 CN CN2009801227842A patent/CN102083856A/en active Pending
- 2009-04-16 RU RU2010146387/10A patent/RU2010146387A/en not_active Application Discontinuation
- 2009-04-16 JP JP2011505204A patent/JP2011517951A/en active Pending
- 2009-04-16 EP EP09743241A patent/EP2288622A4/en not_active Withdrawn
- 2009-04-16 AU AU2009244633A patent/AU2009244633A1/en not_active Abandoned
- 2009-04-16 WO PCT/US2009/040813 patent/WO2009137254A2/en active Application Filing
- 2009-04-16 BR BRPI0910702A patent/BRPI0910702A2/en not_active IP Right Cessation
- 2009-04-16 SG SG2013028790A patent/SG189790A1/en unknown
- 2009-04-16 MX MX2010011345A patent/MX2010011345A/en not_active Application Discontinuation
- 2009-04-16 KR KR1020107025567A patent/KR20110005862A/en not_active Application Discontinuation
- 2009-04-16 CA CA2721683A patent/CA2721683A1/en not_active Abandoned
-
2010
- 2010-10-14 IL IL208718A patent/IL208718A0/en unknown
- 2010-10-15 SV SV2010003704A patent/SV2010003704A/en unknown
- 2010-10-15 CO CO10128682A patent/CO6311000A2/en active IP Right Grant
- 2010-10-15 DO DO2010000311A patent/DOP2010000311A/en unknown
- 2010-10-15 EC EC2010010551A patent/ECSP10010551A/en unknown
- 2010-10-15 CR CR11737A patent/CR11737A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2010146387A (en) | 2012-05-27 |
ECSP10010551A (en) | 2010-11-30 |
CN102083856A (en) | 2011-06-01 |
DOP2010000311A (en) | 2011-02-28 |
CR11737A (en) | 2011-02-07 |
EP2288622A2 (en) | 2011-03-02 |
CA2721683A1 (en) | 2009-11-12 |
WO2009137254A3 (en) | 2010-01-14 |
IL208718A0 (en) | 2010-12-30 |
CO6311000A2 (en) | 2011-08-22 |
WO2009137254A2 (en) | 2009-11-12 |
MX2010011345A (en) | 2011-02-23 |
JP2011517951A (en) | 2011-06-23 |
EP2288622A4 (en) | 2012-04-18 |
KR20110005862A (en) | 2011-01-19 |
BRPI0910702A2 (en) | 2016-07-05 |
SG189790A1 (en) | 2013-05-31 |
AU2009244633A1 (en) | 2009-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2010003704A (en) | MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME | |
DOP2012000030A (en) | MODIFIED FACTOR IX POLIPEPTIDES AND USES OF THE SAME | |
SV2009003393A (en) | FACTOR POLIPEPTIDES VII MODIFICATIONS AND USES OF THE SAME | |
CR20140512A (en) | DEVICES AND METHODS FOR THE MANUFACTURE OF IMPLANT COMPONENT ADDITIVES | |
GT201400166A (en) | SYNTHETIC APELINE MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT | |
CO6331368A2 (en) | MODIFIED POLIPEPTIDE FACTORS VII (FVII) | |
CY1116424T1 (en) | ADENINIS PRODUCTION AS RISK RISK | |
CL2009000393A1 (en) | Pharmaceutical composition comprising a) an activatable pharmaceutical agent, b) a plasmonic active agent; Useful for the treatment of cell proliferation disorders. | |
ECSP12012024A (en) | COMBINED THERAPY FOR CANCER TREATMENT AND RELATED DIAGNOSTIC TESTS | |
UY34566A (en) | 1,4? DIHYDROPIRIMIDINES 4.4? DISUSTITUTED AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B | |
CL2010001160A1 (en) | Compounds derived from 3,8-diazabicyclo [4.2.0] octane and 3,6-diazabicyclo [3.2.0] heptane; pharmaceutical composition; orexin reeptor modulators, useful in the treatment of insomnia. | |
CL2008001626A1 (en) | Compounds derived from fused heterocycles, a pharmaceutical agent that comprises them and their use in the prophylaxis and treatment of cancer. | |
EA201270619A1 (en) | USE OF BETANEHOL FOR THE TREATMENT OF XEROSTOMY | |
BR112013010834B1 (en) | modified factor ix polypeptides and uses thereof | |
MX2015001083A (en) | Modified factor x polypeptides and uses thereof. | |
UY34781A (en) | MODULATORS OF THE COMPLEMENT ROUTE AND USES OF THE SAME | |
UY35703A (en) | ANTIBODIES AGAINST THE INHIBITOR-1 OF THE PLASMINOGEN ACTIVATOR (PAI-1) AND USES OF THE SAME | |
UY29250A1 (en) | CYTOTOXIC AGENTS UNDERSTANDING NEW TAXANES MODIFIED IN C-2.- | |
CR20110630A (en) | CARBOXAMIDE COMPOUNDS AND ITS USE AS CALPAIN INHIBITORS | |
NI201000015A (en) | BUPROPION BROMHYDRATE AND THERAPEUTIC APPLICATIONS | |
DOP2010000251A (en) | EFFECTIVE PARAMYXOVIRUS AS ANTITUMORAL | |
CY1114880T1 (en) | MGLU2 AGONISTS | |
BR112012015461A2 (en) | modified somatotropin boviina polypeptides and their uses | |
CL2020000019A1 (en) | Iiarn agents for the inhibition of alpha-enac expression and methods of use. | |
SV2010003734A (en) | 4- (3-CHLORO-2-FLUOROANILINO) DIFUMARATE SALT -7 METOXI-6 - {[1- (N-METILCARBAMOILMETIL) PIPERIDIN-4-IL-] OXI} QUINAZOLINA |